691 hasil
Menampilkan 1–20 · 0,25 detik · RSS
Journal of Dermatological Treatment
Scopus
ISSN 1471-1753 · Taylor & Francis Group · 691 artikel di indeks
-
Artikel Jurnal
Ivarmacitinib in patients with moderate to severe atopic dermatitis stratified by baseline characteristics: a post-hoc analysis of a phase 3 clinical trial
Background Ivarmacitinib (SHR0302) is a novel and highly selective Janus kinase 1 inhibitor for treating moderate to severe atopic dermatitis (AD).Objective This study aimed to evaluate the impacts of patient characteristics on the efficacy and safety of Ivarmacitinib.Methods This post-hoc analysis…
-
Artikel Jurnal
24-week real world outcomes of nemolizumab in patients with prurigo nodularis
Backgrounds Prurigo nodularis (PN) is a chronic pruritic inflammatory disease associated with immune and neural dysregulation. Although nemolizumab has demonstrated efficacy in clinical trials, real-world post-marketing data remain limited.Objective To evaluate the real-world efficacy, safety, and…
-
Artikel Jurnal
Long-term efficacy and tolerability of clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel for acne: pooled results from two 6-month studies
Aim Given the chronic nature of acne, two 6-month studies were conducted to evaluate the long-term efficacy and tolerability of clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide (BPO) 3.1% gel (CAB)—the only approved triple-combination acne topical—and its effects on…
-
Artikel Jurnal
Risankizumab super responders in moderate-to-severe psoriasis: prevalence, predictors, and long-term maintenance in a multicenter, international, real-world cohort
Background/Objectives The concept of super responders (SRs) has gained increasing attention in psoriasis. However, evidence focusing exclusively on risankizumab remains limited. This multicenter, international, real-world study aimed to assess the prevalence, predictors, and long-term maintenance…
-
Artikel Jurnal
Evidence-based recommendations for the treatment of recurrent aphthous stomatitis: insights from an umbrella review
Objective To compare the effectiveness and safety of pharmacological, physical, and complementary interventions for recurrent aphthous stomatitis (RAS) across clinically relevant outcomes.Methods This umbrella review was conducted according to PRISMA and Cochrane guidance and registered in PROSPERO…
-
Artikel Jurnal
Midface volumization and skin quality enhancement with a hyaluronic acid–polynucleotide hybrid filler: a 24-week prospective open-label study
Background Facial aging is characterized by midface volume loss from structural and dermal atrophy.Objectives To evaluate the efficacy and safety of a hyaluronic acid–polynucleotide (HA–PN) hybrid filler for temporary restoration of anteromedial cheek volume.Methods In this single-center…
-
Artikel Jurnal
Safety, tolerability, and pharmacokinetics of CG2001 in Chinese adult male subjects with androgenetic alopecia: a randomized, double-blind, placebo-controlled, single- and multi-doses, phase 1 clinical study
Objectives Compared with placebo, this phase I study evaluated the safety, tolerability, and pharmacokinetics of CG2001, a novel isopropyl alcohol-free minoxidil-finasteride combination topical foam, in Chinese males with androgenetic alopecia (AGA).Methods In this randomized, double-blind…
-
Artikel Jurnal
Off-label treatment of atopic dermatitis and psoriasis
Objectives Off-label prescribing is a common and often necessary practice in dermatology, as approved treatment options frequently fail to meet the diverse needs of patients. This is particularly relevant in the management of two prevalent inflammatory dermatoses - atopic dermatitis and psoriasis…
-
Artikel Jurnal
Real-world effectiveness and safety of guselkumab in adult patients with facial and/or genital psoriasis: a 52-week analysis from the Italian multicentric GULLIVER study
Objectives Facial and genital plaques are common manifestations of psoriasis, are challenging to treat, and significantly impact patients’ quality of life (QoL).Methods GULLIVER is a prospective, non-interventional study conducted in 2020–2023 in Italy, aimed at examining the effectiveness, safety…
-
Artikel Jurnal
Persistence of interleukin-17 and interleukin-23 inhibitors in patients with plaque psoriasis: a real-world study in Taiwan
Objectives IL-17 inhibitors (IL-17i) and IL-23 inhibitors (IL-23i) are advanced treatments for moderate-to-severe plaque psoriasis. This study aimed to assess the persistence of IL-17i and IL-23i in patients with plaque psoriasis in Taiwan, where a unique healthcare reimbursement policy makes…
-
Artikel Jurnal
Efficacy and safety of topical 3% minoxidil for facial hair enhancement in transmen: a randomized, double-blind, placebo-controlled trial
Objectives Facial hair development is a crucial aspect of gender affirmation for transgender men. Despite testosterone therapy, incomplete facial hair growth remains a common concern. This randomized, double-blind, placebo-controlled trial evaluated topical 3% minoxidil for facial hair enhancement…
-
Artikel Jurnal
Soluble Fas Ligand, an overlooked target of therapy in dermatological and non-dermatological conditions
Background The Fas/Fas Ligand (Fas/FasL) system mediates key physiological and pathological pathways. Therapies targeting this system are currently unavailable due to the complexity of the Fas/FasL pathway and the side effects associated with reduced apoptosis of cancer cells and the lack of…
-
Artikel Jurnal
Real-world outcomes of deucravacitinib in Chinese plaque psoriasis patients: a 24-week prospective study
Aim: Deucravacitinib, a selective tyrosine kinase 2 (TYK2) inhibitor, has demonstrated efficacy in randomized trials for plaque psoriasis, but real-world data in Asian populations remain limited. This 24-week prospective real-world cohort study evaluated the effectiveness and safety of…
-
Artikel Jurnal
Healthcare resource use of patients with mild-moderate psoriasis on systemic treatments: a UK single-center longitudinal retrospective cohort study
Background Healthcare resource utilization (HCRU) costs in those on conventional systemics for mild-moderate psoriasis are poorly described.Objectives This study aimed to describe HRCU, disease severity and health-related quality of life in patients with mild-moderate psoriasis requiring systemic…
-
Artikel Jurnal
JAK inhibition therapy for intractable cutaneous infectious granulomatosis with unknown etiology: a case report
Aim To describe the clinical response to the JAK inhibition, upadacitinib, in a patient with cutaneous infectious granulomatosis.Methods We reported a 36-year-old female with chronic, treatment-resistant facial and leg plaques. Histopathology supported a diagnosis of infectious granuloma, but no…
-
Artikel Jurnal
Comparison of long-term efficacy and safety of different therapeutic approaches for vulvar Lichen sclerosus: a systematic review and meta-analysis
Aim This systematic review and meta-analysis aimed to compare the long-term efficacy and safety of physical therapies (laser and photodynamic therapy) versus conventional topical glucocorticoids for the treatment of vulvar lichen sclerosus (VLS).Materials and methods A total of ten randomized…
-
Artikel Jurnal
Lebrikizumab off-therapy remission sustained up to 38 weeks in atopic dermatitis
Aim of the study Lebrikizumab monotherapy demonstrated efficacy for adults and adolescents with moderate-to-severe atopic dermatitis (AD). This study aims to evaluate the relationship between lebrikizumab serum levels and stable deep response after treatment cessation in Week 16-responder patients…
-
Artikel Jurnal
Raising the bar of efficacy in Atopic Dermatitis: deep response in week 16 responders treated with lebrikizumab over 2 years
Background Lebrikizumab, a high-affinity monoclonal antibody targeting interleukin-13, effectively treats moderate-to-severe atopic dermatitis (AD).Methods Lebrikizumab-treated patients in ADvocate1&2 achieving per-protocol response—IGA (0,1) or EASI 75 at Week 16—were re-randomized 2:2:1 to…